Justin Sherman

Dr. Justin Sherman


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 November 2020 in Diabetes Spectrum
Verified
Journal Article
Closed access
PDF file
JSJustin Sherman
Justin Sherman
JSJustin Sherman
Justin Sherman

1 February 2021 in Diabetes Spectrum
Verified
Journal Article
Open access
PDF file
EHElizabeth B. Hearn
Elizabeth B. Hearn
JSJustin Sherman
Justin Sherman
Glucagon-like peptide 1 (GLP-1) receptor agonists are a safe and effective treatment option for patients with type 2 diabetes (1). Selective activation of the G

1 October 2011 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
JSJustin Sherman
Justin Sherman
DRDaniel M. Riche
Daniel M. Riche
KSKayla R. Stover
Kayla R. Stover
Objective. To evaluate the impact of a physical-assessment learning experience implemented in the problem-based learning (PBL) format of the third year of a doctor of pharmacy (PharmD) program.Design. Students enrolled in a PBL course completed survey instruments to measure knowledge and confidence before and after participating in the learning experience. A simulation stethoscope was used to teach students abnormal pulmonary and cardiovascular sounds in 1-hour sessions for each of 12 PBL groups.Assessment. The 92 students enrolled in the PBL course completed pre- and post-experience survey instruments. Students’ scores on knowledge questions increased significantly (p < 0.0001) from 40.4% ± 11.4% at baseline to 62.5% ± 13.7% and 63.1 ± 11.6%, respectively, on the 2 sets of post-experience questions. Students scored a median of 3 or 4 on a 5-point Likert scale after a learning experience on questions measuring confidence.Conclusion. Use of a simulation stethoscope in a physical-assessment learning experie...

31 March 2019 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
JSJustin Sherman
Justin Sherman
BSBrett L. Smith
Brett L. Smith
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

3 January 2012 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
JSJustin Sherman
Justin Sherman
RWRon W. Welch
Ron W. Welch
THT. Matthew Hill
T. Matthew Hill
CMCorey McEwen
Corey McEwen
Purpose: The purpose of this study was to compare prescriber monitoring for safety and efficacy of medication classes used to treat benign prostatic hyperplasia (BPH). Methods: This was a retrospective chart review of patients diagnosed with BPH who were prescribed medications within a family medicine clinic between January 2008 and August 2010. Patients were divided into those receiving nonselective and uroselective alpha-blockers, 5-alpha reductase inhibitors (5-ARIs), and combination therapy. A chart review was performed with regard to predetermined criteria to monitor how efficacy and adverse effects were assessed by providers in the clinic. Results: A general genitourinary assessment was documented most frequently for patients receiving 5-ARIs and least frequently in patients receiving nonselective alpha-blockers. A digital rectal examination was documented in 11% of patients. Prostate-specific antigen concentrations were assessed evenly across all medication classes and documented in 47% of eligible patients. However, the American Urological Association Symptom Index and quality-of-life questions were not performed on any patients, and assessments of adverse effects were not documented. Conclusion: Although prescribers in a family medicine clinic recorded a general genitourinary assessment for patients receiving BPH medications, a more standardized approach is needed.